Mantle cell lymphoma: Therapeutic strategies are different from CLL
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In contrast to the typical course of chronic lymphocytic lymphoma and despite an indolent lymphoma-like presentation, the clinical outcome of mantle cell lymphoma (MCL) is dismal, with a median survival time of 3 years and virtually no long-term survivors. Most patients are diagnosed with advanced stage III/IV disease. Although clinical studies did not prove a clear superiority of anthracyclin-containing combinations, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like regimens represent the standard therapeutic approach in MCL. Recent randomized studies have shown a benefit of a combined immunochemotherapy strategy (chemotherapy plus rituximab) increasing the complete and overall response rates, whereas further followup is pending for evaluation of the progression-free and overall survival. In patients younger than 65 years, a dose-intensive consolidation comprising high-dose radiochemotherapy and subsequent autologous stem cell transplantation after a CHOP-like induction results in an improved progression-free survival. However, despite the benefits of this multimodal approach, most patients relapse even after high-dose therapy. The only curative approach is allogeneic stem cell transplantation, which may be adapted to the elderly MCL patient cohort by modified dose-reduced conditioning regimens. Prospective randomized trials remain critical to further improve the clinical course of MCL with the addition of newer treatment modalities, such as radioactively labeled antibodies and targeted therapies (eg, flavopiridol and PS-341).
- Medeiros LJ, van Krieken JH, Jaffe ES, Raffeld M: Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990, 76:2086–2090.
- Rosenberg CL, Wong E, Petty EM, et al.: PRAD1, a candidate BLC1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A 1991, 88:9638–9642. CrossRef
- Hiddemann W, Dreyling M, Tiemann M, et al.: Mantle cell lymphomas. Haematologica 1999, 84(Suppl 10):93–95. A short and precise description of the clinical characteristics of MCL.
- Jaffe ES, Campo E, Raffeld M: Mantle cell lymphoma. Semin Hematol 1999, 36:115–127. An excellent histomorphologic characterization of MCL.
- Yatabe Y, Suzuki R, Matsuno Y, et al.: Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int 2001, 51:747–761. CrossRef
- Ruskone-Fourmestraux A, Delmer A, Lavergne A, et al.: Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D’etude des Lymphomes Digestifs. Gastroenterology 1997, 112:7–16. CrossRef
- Oinonen R, Franssila K, Elonen E: Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999, 78:145–149. CrossRef
- Bosch F, Lopez-Guillermo A, Campo E, et al.: Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567–575. CrossRef
- Weisenburger DD, Vose JM, Greiner TC, et al.: Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000, 64:190–196. CrossRef
- Andersen NS, Jensen MK, de Nully Brown P, Geisler CH: A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002, 38:401–408. CrossRef
- Dreyling M: The increasing role of prognostic factors in the choice of treatment: mantle cell lymphoma [abstract]. Ann Oncology 2002, 13(Suppl 2):18.
- Frank C, Zierhut D, Schulz-Ertner D, Wannenmacher M: Centroblastic-centrocytic non-Hodgkin’s lymphoma stage I-III: patterns of failure following radiotherapy. Strahlenther Onkol 2001, 177:597–603. CrossRef
- Zucca E, Roggero E, Pinotti G, et al.: Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257–262.
- Meusers P, Engelhard M, Bartels H, et al.: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989, 7:365–380. CrossRef
- Zinzani PL, Magagnoli M, Moretti L, et al.: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle cell lymphoma. J Clin Oncol 2000, 18:773–779.
- Decaudin D, Bosq J, Tertian G, et al.: Phase II trial of fludarabine monophosphate in patients with mantle cell lymphomas. J Clin Oncol 1998, 16:579–583.
- Samaha H, Dumontet C, Ketterer N, et al.: Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998, 12:1281–1287. CrossRef
- Foran JM, Rohatiner AZ, Coiffier B, et al.: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle cell lymphoma. J Clin Oncol 1999, 17:546–553.
- Rummel MJ, Chow KU, Karakas T, et al.: Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle cell and low grade non-Hodgkin’s lymphoma. Eur J Cancer 2002, 38:1739–1746. CrossRef
- Hiddemann W, Dreyling M, Unterhalt M: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003, 30(Suppl 2):16–20. This paper presents the results of the first randomized study in MCL, suggesting the benefits of combined immunochemotherapy (R-FCM). CrossRef
- Cohen BJ, Moskowitz C, Straus D, et al.: Cyclophosphamide/ fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42:1015–1022. Despite the small and inhomogenous patient population, this study confirms the efficacy of a fludarabine-containing regimen in patients with MCL. CrossRef
- Touati M, Fitoussi O, Jaccard A, Petit B: DHAP regimen for relapsed or refractory low grade lymphomas: a study of 86 cases. Blood 2002, 100:302b.
- Lefrere F, Delmer A, Suzan F, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by highdose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587–593. This phase II study strongly suggests the superiority of a highdose cytarabine-containing chemotherapy in comparison to a standard CHOP regimen. CrossRef
- Romaguera JE, Khouri IF, Kantarjian HM, et al.: Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000, 39:77–85. The results of this dose-intensified MD Anderson (Houston, TX) approach in patients with MCL are remarkable. In addition, this alternating concept was feasible in an elderly patient cohort.
- Seymour JF, Grigg AP, Szer J, Fox RM: Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin’s lymphoma. Cancer 2002, 94:585–593. CrossRef
- Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al.: Efficacy of four different regimens in 64 mantle cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819–2826.
- Coiffier B, Haioun C, Delaby P, et al.: Phase II study of PEG-Itron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated [abstract]. Blood 2001, 98:604a. CrossRef
- Bukowski RM, Tendler C, Cutler D, et al.: Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002, 95:389–396. CrossRef
- Foran JM, Rohatiner AZ, Cunningham D, et al.: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317–324.
- Ghielmini M, Schmitz SF, Burki K, et al.: The effect of rituximab on patients with follicular and mantle cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000, 11:123–126. CrossRef
- Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:176–177.
- Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288–1294. This is the first full paper describing, in more detail, the effect of combined immunochemotherapy (R-CHOP) in patients with MCL. A rather short remission duration was observed. CrossRef
- Hiddemann W, Unterhalt M, Dreyling M, et al.: The addition of rituximab (R) to combination chemotherapy (CT) improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood 2002, 100:92a. These studies showed a superior overall survival after combined immunochemotherapy (R-FCM) in relapsed MCL.
- Gopal AK, Rajendran JG, Petersdorf SH, et al.: Highdose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158–3162. Although the number of patients is small, this study is a proof of principle for the radioimmunochemotherapy in the therapy-refractory entity of MCL. CrossRef
- Behr TM, Griesinger F, Riggert J, et al.: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002, 94(Suppl 4):1363–1372. CrossRef
- Stewart DA, Vose JM, Weisenburger DD, et al.: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995, 6:263–266.
- Milpied N, Gaillard F, Moreau P, et al.: High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645–650. CrossRef
- Hiddemann W, Dreyling MH, Pfreundschuh M, et al.: Myeloablative radiochemotherapy followed by autologous stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL): results of a prospective randomized European intergroup study [abstract]. Blood 2001, 98:861a. The first prospectively randomized study that confirms the benefit of an intensive consolidation concerning progressionfree survival in patients with MCL.
- Andersen NS, Donovan JW, Borus JS, et al.: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212–4221.
- Magni M, Di Nicola M, Devizzi L, et al.: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000, 96:864–869.
- Kroger N, Hoffknecht M, Kruger W, et al.: Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000, 79:578–580. CrossRef
- Martinez C, Carreras E, Rovira M, et al.: Patients with mantle cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 2000, 26:677–679. CrossRef
- Berdeja JG, Jones RJ, Zahurak ML, et al.: Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant 2001, 7:561–567. CrossRef
- Khouri FI, Saliba RM, Younes A, et al.: Allogeneic transplantation for poor risk mantle cell lymphoma (MCL): chemosensitivity predicts superior outcome [abstract]. Blood 2002, 100:416a.
- Lin TS, Howard OM, Neuberg DS, et al.: Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002, 43:793–797. CrossRef
- Pham L, Tamayo A, Lo P, et al.: Anti-tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells [abstract]. Blood 2001, 98:465a.
- Mantle cell lymphoma: Therapeutic strategies are different from CLL
Current Treatment Options in Oncology
Volume 4, Issue 3 , pp 219-226
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links